Survival benefit of living donor liver transplant for patients with hepatocellular carcinoma.
Hepatocellular carcinoma
Living donor liver transplant
Transplant outcomes
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
received:
28
03
2024
accepted:
12
07
2024
medline:
22
7
2024
pubmed:
22
7
2024
entrez:
22
7
2024
Statut:
aheadofprint
Résumé
With the increasing incidence of hepatocellular carcinoma (HCC) in both the United States and globally, the role of liver transplantation in management continues to be an area of active conversation as it is often considered the gold standard in the treatment of HCC. The use of living donor liver transplantation (LDLT) and the indications in the setting of malignancy, both generally and in HCC specifically, are frequently debated. In terms of both overall survival and recurrence-free survival, LDLT is at least equivalent to DDLT, especially when performed for disease within Milan criteria. Emerging and compelling evidence suggests that LDLT is superior to DDLT in treating HCC as there is a significant decrease in waitlist mortality. As the oncologic indications for liver transplantation continue to expand and the gap between organ demand and organ availability continues to worsen, high volumes centers should consider using LDLT to shrink the ever-expanding waitlist.
Identifiants
pubmed: 39037684
doi: 10.1007/s13304-024-01947-8
pii: 10.1007/s13304-024-01947-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Italian Society of Surgery (SIC).
Références
Dai WC, Chan SC, Chok KSH et al (2014) Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter. HPB 16(8):749–757. https://doi.org/10.1111/HPB.12212
doi: 10.1111/HPB.12212
pubmed: 24467735
pmcid: 4113258
Lin CC, Chen CL (2016) Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. Hepatobil Surg Nutr. 5(5):415–421. https://doi.org/10.21037/hbsn.2016.08.02
doi: 10.21037/hbsn.2016.08.02
Gondolesi G, Muñoz L, Matsumoto C et al (2002) Hepatocellular carcinoma: a prime indication for living donor liver transplantation. J Gastrointest Surg 6(1):102–107. https://doi.org/10.1016/S1091-255X(01)00024-5
doi: 10.1016/S1091-255X(01)00024-5
pubmed: 11986025
Fisher RA, Kulik LM, Freise CE et al (2007) Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transpl 7(6):1601–1608. https://doi.org/10.1111/J.1600-6143.2007.01802.X
doi: 10.1111/J.1600-6143.2007.01802.X
Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–700. https://doi.org/10.1056/NEJM199603143341104
doi: 10.1056/NEJM199603143341104
pubmed: 8594428
Bhatti ABH, Qureshi AI, Tahir R et al (2020) When to call it off: Defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma. BMC Cancer 20(1):1–9. https://doi.org/10.1186/S12885-020-07238-W/FIGURES/3
doi: 10.1186/S12885-020-07238-W/FIGURES/3
Halazun KJ, Tabrizian P, Najjar M et al (2018) Is it time to abandon the Milan criteria? Results of a bicoastal US collaboration to redefine hepatocellular carcinoma liver transplantation selection policies. Ann Surg 268(4):690–699. https://doi.org/10.1097/SLA.0000000000002964
doi: 10.1097/SLA.0000000000002964
pubmed: 30048307
Mehta N, Bhangui P, Yao FY et al (2020) Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation. Published online 2020, pp 1136–1142. https://doi.org/10.1097/TP.0000000000003174
Kulik LM, Fisher RA, Rodrigo DR et al (2012) Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transpl 12(11):2997–3007. https://doi.org/10.1111/j.1600-6143.2012.04272.x
doi: 10.1111/j.1600-6143.2012.04272.x
Soejima Y, Taketomi A, Yoshizumi T et al (2007) Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 83(7):893–899. https://doi.org/10.1097/01.TP.0000259015.46798.EC
doi: 10.1097/01.TP.0000259015.46798.EC
pubmed: 17460559
Liang W, Wu L, Ling X et al (2012) Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 18(10):1226–1236. https://doi.org/10.1002/LT.23490
doi: 10.1002/LT.23490
pubmed: 22685095
Zhu B, Wang J, Li H, Chen X, Zeng Y (2019) Living or deceased organ donors in liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. HPB 21(2):133–147. https://doi.org/10.1016/J.HPB.2018.11.004
doi: 10.1016/J.HPB.2018.11.004
pubmed: 30503300
Lai Q, Sapisochin G, Gorgen A et al (2021) Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant. JAMA Surg 156(9):e213112–e213112. https://doi.org/10.1001/JAMASURG.2021.3112
doi: 10.1001/JAMASURG.2021.3112
pubmed: 34259797
pmcid: 8281041
Halazun KJ, Patzer RE, Rana AA et al (2014) Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 60(6):1957–1962. https://doi.org/10.1002/HEP.27272
doi: 10.1002/HEP.27272
pubmed: 24954365
Lo CM, Fan ST, Liu CL, Chan SC, Ng IOL, Wong J (2007) Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 94(1):78–86. https://doi.org/10.1002/BJS.5528
doi: 10.1002/BJS.5528
pubmed: 17016793
Goldaracena N, Gorgen A, Doyle A et al (2019) Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J Hepatol 70(4):666–673. https://doi.org/10.1016/J.JHEP.2018.12.029
doi: 10.1016/J.JHEP.2018.12.029
pubmed: 30630009
Gondolesi GE, Roayaie S, Muñoz L et al (2004) Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 239(2):142–149. https://doi.org/10.1097/01.SLA.0000109022.32391.EB
doi: 10.1097/01.SLA.0000109022.32391.EB
pubmed: 14745320
pmcid: 1356205
Lo CM, Fan ST, Liu CL, Chan SC, Wong J (2004) The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 10(3):440–447. https://doi.org/10.1002/LT.20097
doi: 10.1002/LT.20097
pubmed: 15004774
Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8(10):ajlts0080873. https://doi.org/10.1053/jlts.2002.34923
Bhangui P, Saigal S, Gautam D et al (2021) Incorporating tumor biology to predict hepatocellular carcinoma recurrence in patients undergoing living donor liver transplantation using expanded selection criteria. Liver Transpl 27(2):209–221. https://doi.org/10.1002/LT.25956
doi: 10.1002/LT.25956
pubmed: 33253492
Kaido T, Mori A, Ogura Y et al (2011) Recurrence of hepatocellular carcinoma after living donor liver transplantation: what is the current optimal approach to prevent recurrence? World J Surg 35(6):1355–1359. https://doi.org/10.1007/S00268-011-1045-3/FIGURES/4
doi: 10.1007/S00268-011-1045-3/FIGURES/4
pubmed: 21424873
Wong TCL, Ng KKC, Fung JYY et al (2019) Long-term survival outcome between living donor and deceased donor liver transplant for hepatocellular carcinoma: intention-to-treat and propensity score matching analyses. Ann Surg Oncol 26(5):1454–1462. https://doi.org/10.1245/S10434-019-07206-0/TABLES/4
doi: 10.1245/S10434-019-07206-0/TABLES/4
pubmed: 30737669
Ninomiya M, Shirabe K, Facciuto ME et al (2015) Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma. J Am Coll Surg 220(3):297-304.e3. https://doi.org/10.1016/J.JAMCOLLSURG.2014.12.009
doi: 10.1016/J.JAMCOLLSURG.2014.12.009
pubmed: 25617912
Lee S, Song GW, Kim KW, Kwon JH, Lee SG (2021) Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma within or beyond the milan criteria: comparable long-term outcomes. Transpl Proc 53(1):92–97. https://doi.org/10.1016/j.transproceed.2020.10.012
doi: 10.1016/j.transproceed.2020.10.012
Kaido T, Morita S, Tanaka S et al (2015) Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study. Dis Mark 2015:425926. https://doi.org/10.1155/2015/425926
doi: 10.1155/2015/425926
Yoshizumi T, Harimoto N, Itoh S et al (2016) Living donor liver transplantation for hepatocellular carcinoma within Milan criteria in the present era. Anticancer Res 36(1):439–445
pubmed: 26722079
Shimada M, Yonemura Y, Ijichi H et al (2005) Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transpl Proc 37(2):1177–1179. https://doi.org/10.1016/J.TRANSPROCEED.2004.12.030
doi: 10.1016/J.TRANSPROCEED.2004.12.030
Wai CT, Woon WA, Tan YM, Lee KH, Tan KC (2012) Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation. Transpl Proc 44(2):516–519. https://doi.org/10.1016/J.TRANSPROCEED.2012.01.032
doi: 10.1016/J.TRANSPROCEED.2012.01.032
Abdel-Wahab M, Sultan AM, Fathy OM et al (2013) Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 60(128):1847–1853
pubmed: 24719918
Hung HC, Lee JC, Wang YC et al (2022) Living-donor liver transplantation for hepatocellular carcinoma: impact of the MELD score and predictive value of NLR on survival. Curr Oncol 29(6):3881–3893. https://doi.org/10.3390/curroncol29060310
doi: 10.3390/curroncol29060310
pubmed: 35735419
pmcid: 9221955
Halazun KJ, Hardy MA, Rana AA et al (2009) Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 250(1):141–151. https://doi.org/10.1097/SLA.0b013e3181a77e59
doi: 10.1097/SLA.0b013e3181a77e59
pubmed: 19561458
Sotiropoulos GC, Malago M, Machairas N, Fouzas I, Paul A (2019) AGMA score: a novel prognostic score for patients undergoing liver transplant for hepatocellular carcinoma. Transpl Proc 51(6):1923–1925. https://doi.org/10.1016/J.TRANSPROCEED.2019.05.015
doi: 10.1016/J.TRANSPROCEED.2019.05.015
Mehta N, Heimbach J, Harnois DM et al (2017) Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 3(4):493–500. https://doi.org/10.1001/jamaoncol.2016.5116
doi: 10.1001/jamaoncol.2016.5116
pubmed: 27838698
pmcid: 5395317
Mehta N, Dodge JL, Roberts JP, Yao FY (2018) Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant 18(5):1206–1213. https://doi.org/10.1111/ajt.14549
doi: 10.1111/ajt.14549
pubmed: 29068145
Itoh S, Yoshizumi T, Kimura K et al (2016) Effect of sarcopenic obesity on outcomes of living-donor liver transplantation for hepatocellular carcinoma. Anticancer Res 36(6):3029–3034
pubmed: 27272822
Toshima T, Yoshizumi T, Kosai-Fujimoto Y et al (2020) Prognostic impact of osteopenia in patients who underwent living donor liver transplantation for hepatocellular carcinoma. World J Surg 44(1):258–267. https://doi.org/10.1007/s00268-019-05206-5
doi: 10.1007/s00268-019-05206-5
pubmed: 31624895
Terrault NA, Shiffman ML, Lok ASF et al (2007) Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 13(1):122. https://doi.org/10.1002/LT.20995
doi: 10.1002/LT.20995
pubmed: 17192908
pmcid: 3155862
Nacif LS, Zanini LY, Waisberg DR et al (2020) Adult-to-adult living donor liver transplant: hemodynamic evaluation, prognosis, and recipient selection. Transpl Proc 52(5):1299–1302. https://doi.org/10.1016/j.transproceed.2020.02.073
doi: 10.1016/j.transproceed.2020.02.073
Sandhu L, Sandroussi C, Guba M et al (2012) Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 18(3):315–322. https://doi.org/10.1002/LT.22477
doi: 10.1002/LT.22477
pubmed: 22140013
Zakaria HM, Sallam AN, Ayoub II et al (2017) Predictors of outcome of living donor liver transplantation for hepatocellular carcinoma. Indian J Surg 79(4):299–307. https://doi.org/10.1007/S12262-016-1474-1/TABLES/6
doi: 10.1007/S12262-016-1474-1/TABLES/6
pubmed: 28827903
Pavel MC, Sanchez Cabus S, Crespo G et al (2018) Role of adult living donor liver transplantation in the treatment of hepatocellular carcinoma within and beyond milan criteria: a comparative study. Transpl Proc 50(5):1386–1395. https://doi.org/10.1016/J.TRANSPROCEED.2018.02.093
doi: 10.1016/J.TRANSPROCEED.2018.02.093
Yao FY, Bass NM, Ascher NL, Roberts JP (2004) Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl 10(5):621–630. https://doi.org/10.1002/LT.20159
doi: 10.1002/LT.20159
pubmed: 15108253
Park HW, Hwang S, Ahn CS et al (2013) Long-term survival outcomes for living donor liver transplant recipients with pathologically nonviable hepatocellular carcinoma. Transpl Proc 45(8):3032–3034. https://doi.org/10.1016/J.TRANSPROCEED.2013.08.027
doi: 10.1016/J.TRANSPROCEED.2013.08.027
Yao FY, Mehta N, Flemming J et al (2015) Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 61(6):1968–1977. https://doi.org/10.1002/hep.27752
doi: 10.1002/hep.27752
pubmed: 25689978
Halazun KJ, Rosenblatt RE, Mehta N et al (2021) Dynamic α-fetoprotein response and outcomes after liver transplant for hepatocellular carcinoma. JAMA Surg 156(6):559. https://doi.org/10.1001/jamasurg.2021.0954
doi: 10.1001/jamasurg.2021.0954
pubmed: 33950167
pmcid: 8100910
Di Sandro S, Centonze L, Catellani B et al (2024) Current role and perspectives of living donor liver transplantation for hepatocellular carcinoma: systematic review of the past 20 years. Updates Surg. https://doi.org/10.1007/S13304-024-01862-Y/TABLES/3
Ntellas P, Chau I (2024) Updates on systemic therapy for hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. https://doi.org/10.1200/EDBK_430028
doi: 10.1200/EDBK_430028
pubmed: 38175973
Amara D, Parekh J, Sudan D et al (2022) Surgical complications after living and deceased donor liver transplant: the NSQIP transplant experience. Clin Transpl 36(6):e14610. https://doi.org/10.1111/ctr.14610
doi: 10.1111/ctr.14610
Vitale A, Volk M, Cillo U (2013) Transplant benefit for patients with hepatocellular carcinoma. World J Gastroenterol 19(48):9183–9188. https://doi.org/10.3748/wjg.v19.i48.9183
doi: 10.3748/wjg.v19.i48.9183
pubmed: 24409046
pmcid: 3882392
Pomfret EA, Lodge JPA, Villamil FG, Siegler M (2011) Should we use living donor grafts for patients with hepatocellular carcinoma? ethical considerations. Liver Transpl 17(S2):S128–S132. https://doi.org/10.1002/LT.22356
doi: 10.1002/LT.22356
pubmed: 21656657
Magyar CTJ, Choi WJ, Li Z et al (2024) The aim of donor safety: surgical approaches and current results. Updates Surg. https://doi.org/10.1007/s13304-024-01881-9
doi: 10.1007/s13304-024-01881-9
pubmed: 38916620
Bhangui P, Vibert E, Majno P et al (2011) Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 53(5):1570–1579. https://doi.org/10.1002/HEP.24231
doi: 10.1002/HEP.24231
pubmed: 21520172
Sotiropoulos GC, Lang H, Nadalin S et al (2007) Liver transplantation for hepatocellular carcinoma: University Hospital Essen experience and metaanalysis of prognostic factors. J Am Coll Surg 205(5):661–675. https://doi.org/10.1016/j.jamcollsurg.2007.05.023
doi: 10.1016/j.jamcollsurg.2007.05.023
pubmed: 17964442
Sugawara Y, Kokudo N (2008) Surgical treatment of hepatocellular carcinoma: comparison of resection and transplantation. Oncology 75(Suppl 1):119–123. https://doi.org/10.1159/000173433
doi: 10.1159/000173433
pubmed: 19092281
Di Sandro S, Slim AO, Giacomoni A et al (2009) Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. Transpl Proc 41(4):1283–1285. https://doi.org/10.1016/J.TRANSPROCEED.2009.03.022
doi: 10.1016/J.TRANSPROCEED.2009.03.022
Vakili K, Pomposelli JJ, Cheah YL et al (2009) Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transpl 15(12):1861–1866. https://doi.org/10.1002/lt.21940
doi: 10.1002/lt.21940
pubmed: 19938113
Roma J, Balbi E, Pacheco-Moreira L et al (2012) Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma. Transpl Proc 44(8):2423–2427. https://doi.org/10.1016/J.TRANSPROCEED.2012.07.026
doi: 10.1016/J.TRANSPROCEED.2012.07.026
Ivanics T, Claasen MPAW, Samstein B et al (2024) Living donor liver transplantation for hepatocellular carcinoma within and outside traditional selection criteria. Ann Surg 279(1):104–111. https://doi.org/10.1097/SLA.0000000000006049
doi: 10.1097/SLA.0000000000006049
pubmed: 37522174
Akamatsu N, Sugawara Y, Kokudo N (2014) Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 3(2):108–118. https://doi.org/10.1159/000343866
doi: 10.1159/000343866
pubmed: 24945001
pmcid: 4057790
Park MS, Lee KW, Suh SW et al (2014) Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation 97(1):71–77. https://doi.org/10.1097/TP.0b013e3182a68953
doi: 10.1097/TP.0b013e3182a68953
pubmed: 24056623